Document Detail

Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents.
MedLine Citation:
PMID:  10098948     Owner:  NLM     Status:  MEDLINE    
To account for severity of disease in patients with erectile dysfunction, we introduced a progressive treatment technique using four protocols of drug injections. The study group consisted of 452 men aged 26-85 gamma with erectile dysfunction. Protocol I. All patients began with a combination of papaverine and Regitine in doses adjusted to the estimated severity of dysfunction and to age, up to a maximum dose of 25 mg papaverine and 1.5 mg of Regitine. Protocol II. Patients who could not achieve sufficient rigidity on protocol I were switched to prostin VR, to a maximum of 25 mcg. Protocol III. Patients who failed protocol II received papaverine, Regitine and prostin VR. Protocol IV. Patients who failed protocol III received atropine sulfate (0.02-0.06 mg) in addition to papaverine, Regitine and prostin. Sufficient rigidity was achieved as follows: Protocol I=305 (67.4%) of the original cohort; Protocol II= 61 of the 147 failures with Protocol I (41.5%); Protocol III = 55 of the 86 failures with Protocol 11 (63.9%); Protocol IV = 20 of the remaining 31 patients (64.5%). Overall, sustained rigidity was achieved in 441 of the 452 patients (97.5%). Eleven patients (2.5%) failed all four protocols and were offered a penile prosthesis. Therefore, using our progressive method, by starting with the most available and inexpensive drugs, patients with erectile dysfunction can be given optimal treatment according to the severity of their disease. The success rate is high while costs are kept to a minimum.
J Shmueli; S Israilov; E Segenreich; J Baniel; P Livne
Related Documents :
7662688 - Depo-provera in adolescents: effects of early second injection or prior oral contracept...
8609258 - Risk assessment of polymyositis/dermatomyositis after treatment with injectable bovine ...
10460188 - Double blind glucocorticoid controlled trial of samarium-153 particulate hydroxyapatite...
10098948 - Progressive treatment of erectile dysfunction with intracorporeal injections of differe...
1119398 - Hemodynamic consequences of total removal of the tricuspid valve without prosthetic rep...
12804408 - Antibiotics versus placebo for prevention of postoperative infection after appendicectomy.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of impotence research     Volume:  11     ISSN:  0955-9930     ISO Abbreviation:  Int. J. Impot. Res.     Publication Date:  1999 Feb 
Date Detail:
Created Date:  1999-05-06     Completed Date:  1999-05-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9007383     Medline TA:  Int J Impot Res     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  15-9     Citation Subset:  IM    
Andrology Unit, Institute of Urology, Rabin Medical Center, Petah Tiqva, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Alprostadil / adverse effects,  therapeutic use
Atropine / adverse effects,  therapeutic use
Erectile Dysfunction / drug therapy*
Middle Aged
Papaverine / adverse effects,  therapeutic use
Penile Erection / drug effects*
Penis / drug effects*
Phentolamine / adverse effects,  therapeutic use
Vasodilator Agents / administration & dosage*,  adverse effects,  therapeutic use*
Reg. No./Substance:
0/Vasodilator Agents; 50-60-2/Phentolamine; 51-55-8/Atropine; 58-74-2/Papaverine; 745-65-3/Alprostadil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhanced contractility of rabbit corpus cavernosum smooth muscle by oxidized low density lipoprotein...
Next Document:  Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.